IGF1R and pancreatic neoplasm: Similarly, a Phase II trial of cixutumumab (an IGF-1R mAb antagonist) combined with erlotinib and gemcitabine for stage IV pancreatic cancer also failed to extend progression-free survival (Philip et al., 2014).